Mitsubishi UFJ Asset Management Co. Ltd. Sells 108,494 Shares of Liquidia Corporation $LQDA

Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in shares of Liquidia Corporation (NASDAQ:LQDA) by 63.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,682 shares of the company’s stock after selling 108,494 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.07% of Liquidia worth $769,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in Liquidia by 2.9% during the 1st quarter. Bank of New York Mellon Corp now owns 194,131 shares of the company’s stock worth $2,863,000 after buying an additional 5,547 shares during the period. Bleakley Financial Group LLC increased its position in shares of Liquidia by 6.4% during the first quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company’s stock worth $373,000 after acquiring an additional 1,523 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Liquidia by 34.4% during the first quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock worth $619,000 after acquiring an additional 10,756 shares during the period. Hurley Capital LLC acquired a new stake in shares of Liquidia during the first quarter worth $32,000. Finally, CenterBook Partners LP bought a new stake in Liquidia in the 1st quarter valued at $1,786,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Up 4.1%

NASDAQ:LQDA opened at $28.04 on Friday. Liquidia Corporation has a twelve month low of $9.71 and a twelve month high of $29.94. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -19.47 and a beta of 0.12. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock’s 50 day moving average price is $24.40 and its two-hundred day moving average price is $20.27.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business’s revenue was up 1106.7% on a year-over-year basis. Equities research analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other news, insider Scott Moomaw sold 4,900 shares of Liquidia stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $114,709.00. Following the completion of the transaction, the insider owned 153,462 shares of the company’s stock, valued at $3,592,545.42. This trade represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Dana Boyle sold 1,238 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $23.41, for a total transaction of $28,981.58. Following the completion of the sale, the chief accounting officer directly owned 185,411 shares in the company, valued at approximately $4,340,471.51. The trade was a 0.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 920,522 shares of company stock valued at $25,512,207. 26.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HC Wainwright increased their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of Liquidia in a report on Monday, November 3rd. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. Wells Fargo & Company started coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price target for the company. Finally, Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $38.56.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).